Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
biomarker
cerebrospinal fluid
enzyme-linked immunoabsorbent assay
mass spectrometry
round robin
α-synuclein
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
06
04
2018
revised:
06
07
2018
revised:
14
08
2018
accepted:
15
08
2018
pubmed:
21
8
2018
medline:
19
3
2020
entrez:
21
8
2018
Statut:
ppublish
Résumé
α-Synuclein is the major component of Lewy bodies and a candidate biomarker for neurodegenerative diseases in which Lewy bodies are common, including Parkinson's disease and dementia with Lewy bodies. A large body of literature suggests that these disorders are characterized by reduced concentrations of α-synuclein in cerebrospinal fluid (CSF), with overlapping concentrations compared to healthy controls and variability across studies. Several reasons can account for this variability, including technical ones, such as inter-assay and inter-laboratory variation (reproducibility). We compared four immunochemical methods for the quantification of α-synuclein concentration in 50 unique CSF samples. All methods were designed to capture most of the existing α-synuclein forms in CSF ('total' α-synuclein). Each of the four methods showed high analytical precision, excellent correlation between laboratories (R
Identifiants
pubmed: 30125936
doi: 10.1111/jnc.14569
pmc: PMC6587944
doi:
Substances chimiques
Biomarkers
0
alpha-Synuclein
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-138Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Informations de copyright
© 2018 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Références
Neurosci Lett. 2009 Feb 6;450(3):332-5
pubmed: 19022350
Brain. 2010 Mar;133(Pt 3):713-26
pubmed: 20157014
Biomark Med. 2010 Oct;4(5):683-99
pubmed: 20945981
Neurology. 2010 Nov 16;75(20):1766-72
pubmed: 20962290
Lancet Neurol. 2011 Mar;10(3):230-40
pubmed: 21317042
Alzheimer Dis Assoc Disord. 2012 Jul-Sep;26(3):213-6
pubmed: 22037599
J Biol Chem. 2012 Aug 17;287(34):28243-62
pubmed: 22718772
Biomark Med. 2012 Aug;6(4):369-70
pubmed: 22917138
Arch Neurol. 2012 Nov;69(11):1445-52
pubmed: 22925882
PLoS One. 2013;8(1):e53250
pubmed: 23308173
Pharmacol Ther. 2013 Jun;138(3):311-22
pubmed: 23384597
Acta Neuropathol. 2013 Nov;126(5):683-97
pubmed: 23812319
JAMA Neurol. 2013 Oct;70(10):1277-87
pubmed: 23979011
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S76-9
pubmed: 24262194
PLoS One. 2013 Nov 25;8(11):e81654
pubmed: 24282614
Alzheimers Dement. 2014 Oct;10(5 Suppl):S290-8
pubmed: 24439167
Alzheimers Res Ther. 2014 May 07;6(3):25
pubmed: 24987465
Neurobiol Aging. 2015 Sep;36(9):2587-96
pubmed: 26093515
J Neurochem. 2016 Oct;139 Suppl 1:290-317
pubmed: 26452984
Alzheimers Dement. 2016 May;12(5):517-26
pubmed: 26555316
Ann Clin Transl Neurol. 2016 Jan 01;3(3):154-65
pubmed: 27042676
Mol Cell Proteomics. 2016 Oct;15(10):3126-3138
pubmed: 27507836
J Neurochem. 2016 Nov;139(4):651-658
pubmed: 27579672
Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818
pubmed: 27752516
J Alzheimers Dis. 2016 Nov 19;55(2):813-822
pubmed: 27792012
Alzheimers Dement. 2017 Jun;13(6):710-719
pubmed: 27870938
JAMA Neurol. 2017 Feb 1;74(2):163-172
pubmed: 27918765
Neurol Clin. 2017 May;35(2):325-338
pubmed: 28410662
Mov Disord. 2017 Oct;32(10):1389-1400
pubmed: 28880418
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107